Finepoint Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Finepoint Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,633,147	Closed	-$2.51M	–	1
2020 Q4	$2.51M	Buy	+3,633,147	New	+$7.74M	100%	1

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Finepoint Capital's BMY.RT Position: Q1 2021 in Review

Finepoint Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,633,147 shares — an estimated $2.51M sold.

Finepoint Capital first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $2.51M in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Finepoint Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Finepoint Capital sold 3,633,147 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2.51M.
Finepoint Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
Finepoint Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.51M in Q4 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Finepoint Capital's 13F filing for Q1 2021.